Thrombosis catheter development receives major funding

Graphic of lungs with pulmonary embolism

Flow Medical, a Chicago-based medical technology company specializing in solutions for venous thromboembolism (VTE), has completed a $2 million Friends and Family funding round.

Accoring to the company, the influx of money will accelerate the development of its novel thrombolysis catheter for the treatment of acute pulmonary embolism.

The technology behind the catheter was conceived by Drs. Jonathan Paul, MD, and Osman Ahmed, MD, at the University of Chicago Medical Center in 2020, as they sought a way to provide more targeted and precise therapy for PE patients. Flow Medical was developed around that technology.

The thrombolytic catheter offers a minimally invasive solution for the endovascular treatment of PE. The funding raised will be used for further research and development of the catheter along with regulatory activities.

Jennifer Fried, CEO of Flow Medical, said the funding will be a huge step forward for the catheter and for the potential treatment of PE.

“This investment not only validates the potential of this groundbreaking technology, but also propels us toward our goal of revolutionizing the treatment landscape for PE,” she said. “We are grateful for the confidence our Friends and Family investors have placed in our team and our vision.”

More in Pulmonary
Page 1 of 16
Next Page